Literature DB >> 25198363

Chronic non-bacterial osteomyelitis in childhood - a comprehensive review.

Henner Morbach, Hermann J Girschick1.   

Abstract

The clinical picture of childhood chronic recurrent multifocal osteomyelitis (CRMO) is characterized by an aseptic chronic osteomyelitis, most often affecting the metaphyses of the long bones. Skin inflammation (palmoplantar pustulosis, psoriatic lesions, acne) and inflammatory bowel disease may be associated with CRMO and therefore subsume this disease into the entity of SAPHO syndrome. Deregulated cytokine/chemokine expression in myeloid cells seems to drive chronic inflammation of the disease. NSAIDs may reduce pain, but additional second-line treatments (DMARDs, biologicals) are needed to treat persisting or progressing inflammation in a significant number of patients. The use of bisphosphonates may be a promising option in treating NSAID-refractory osteomyelitis in CRMO.

Entities:  

Year:  2013        PMID: 25198363     DOI: 10.2174/1573397111309010006

Source DB:  PubMed          Journal:  Curr Rheumatol Rev        ISSN: 1573-3971


  3 in total

1.  Assessment of disease activity using a whole-body MRI derived radiological activity index in chronic nonbacterial osteomyelitis.

Authors:  Martina Capponi; Denise Pires Marafon; Flaminia Rivosecchi; Yongdong Zhao; Manuela Pardeo; Virginia Messia; Laura Tanturri de Horatio; Paolo Tomà; Fabrizio De Benedetti; Antonella Insalaco
Journal:  Pediatr Rheumatol Online J       Date:  2021-08-14       Impact factor: 3.054

2.  Chronic nonbacterial osteomyelitis involving the mandible: A case report.

Authors:  Gabriele Bocchialini; Luca Ferrari; Manuela Rossini; Anna Bozzola; Dante Burlini
Journal:  Int J Surg Case Rep       Date:  2017-06-15

3.  Genetic variants in FBLIM1 gene do not contribute to SAPHO syndrome and chronic recurrent multifocal osteomyelitis in typical patient groups.

Authors:  Gunter Assmann; Michaela Köhm; Volker Schuster; Frank Behrens; Rotraut Mössner; Nina Magnolo; Vinzenz Oji; Harald Burkhardt; Ulrike Hüffmeier
Journal:  BMC Med Genet       Date:  2020-05-12       Impact factor: 2.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.